Literature DB >> 24468317

Autologous stem cell transplantation for T-cell lymphomas.

Giulia Perrone, Perrone Giulia1, Paolo Corradini2.   

Abstract

Peripheral T-cell lymphomas (PTCLs) are a rare and heterogeneous group of T-cell malignancies characterized by a very poor outcome. The optimal treatment for PTCLs remains controversial. The role of stem cell transplantation in PTCLs has been investigated; however, no randomized control studies specifically dedicated to PTCLs are currently available. Several retrospective and prospective studies have suggested that high-dose chemotherapy (HDT) followed by autologous stem cell transplantation (ASCT) may improve the survival in patients with chemosensitive T-cell lymphoma, either upfront or as salvage treatment. This review provides a summary of the current literature with the intent to explore the role of ASCT in various clinical scenarios.
© 2013 Elsevier Inc. All rights reserved.

Entities:  

Mesh：

Year:  2013        PMID： 24468317     DOI： 10.1053/j.seminhematol.2013.11.002

Source DB:  PubMed          Journal:  Semin Hematol        ISSN： 0037-1963            Impact factor:   3.851


  7 in total

Review 1.  Bone Marrow Transplantation for Peripheral T-Cell Non-Hodgkins' Lymphoma in First Remission.

Authors:  Manish Sharma; Barbara Pro
Journal:  Curr Treat Options Oncol       Date:  2015-07

Review 2.  Carmustine replacement in intensive chemotherapy preceding reinjection of autologous HSCs in Hodgkin and non-Hodgkin lymphoma: a review.

Authors:  G Damaj; J Cornillon; K Bouabdallah; R Gressin; S Vigouroux; T Gastinne; F Ranchon; H Ghésquières; G Salles; I Yakoub-Agha; E Gyan
Journal:  Bone Marrow Transplant       Date:  2017-01-23       Impact factor: 5.483

3.  Brentuximab vedotin with chemotherapy for CD30-positive peripheral T-cell lymphoma (ECHELON-2): a global, double-blind, randomised, phase 3 trial.

Authors:  Steven Horwitz; Owen A O'Connor; Barbara Pro; Tim Illidge; Michelle Fanale; Ranjana Advani; Nancy L Bartlett; Jacob Haaber Christensen; Franck Morschhauser; Eva Domingo-Domenech; Giuseppe Rossi; Won Seog Kim; Tatyana Feldman; Anne Lennard; David Belada; Árpád Illés; Kensei Tobinai; Kunihiro Tsukasaki; Su-Peng Yeh; Andrei Shustov; Andreas Hüttmann; Kerry J Savage; Sam Yuen; Swaminathan Iyer; Pier Luigi Zinzani; Zhaowei Hua; Meredith Little; Shangbang Rao; Joseph Woolery; Thomas Manley; Lorenz Trümper
Journal:  Lancet       Date:  2018-12-04       Impact factor: 79.321

Review 4.  Profile of belinostat for the treatment of relapsed or refractory peripheral T-cell lymphoma.

Authors:  Andrew Bodiford; Megan Bodge; Mahsa S Talbott; Nishitha M Reddy
Journal:  Onco Targets Ther       Date:  2014-10-24       Impact factor: 4.147

5.  First-line therapy of peripheral T-cell lymphoma: extension and long-term follow-up of a study investigating the role of autologous stem cell transplantation.

Authors:  M Wilhelm; M Smetak; P Reimer; E Geissinger; T Ruediger; B Metzner; N Schmitz; A Engert; K Schaefer-Eckart; J Birkmann
Journal:  Blood Cancer J       Date:  2016-07-29       Impact factor: 11.037

6.  BEAM-Modified Conditioning Therapy with Cisplatin+Dexamethasone Instead of Carmustine Prior to Autologous Hematopoietic Stem Cell Transplantation (HSCT) in Patients with Hodgkin and Non-Hodgkin Lymphoma.

Authors:  Ana Lucia Ron-Magaña; Omar Eduardo Fernandez-Vargas; Esperanza Barrera-Chairez; Carlos Silvestre Ron-Guerrero; Ana Jaqueline Bañuelos-Ávila
Journal:  Ann Transplant       Date:  2019-10-22       Impact factor: 1.530

7.  NK Cell Subgroups, Phenotype, and Functions After Autologous Stem Cell Transplantation.

Authors:  Benedikt Jacobs; Sara Tognarelli; Kerstin Poller; Peter Bader; Andreas Mackensen; Evelyn Ullrich
Journal:  Front Immunol       Date:  2015-11-24       Impact factor: 7.561
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.